GOSS Gossamer Bio Inc
Price (delayed)
$0.9785
Market cap
$222.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.25
Enterprise value
$378.18M
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an
Highlights
GOSS's EPS has soared by 79% year-on-year and by 3.8% since the previous quarter
Gossamer Bio's net income has soared by 69% YoY and by 21% from the previous quarter
GOSS's equity has shrunk by 53% YoY and by 46% QoQ
Key stats
What are the main financial stats of GOSS
Market
Valuations
Earnings
Shares outstanding
227.22M
Market cap
$222.34M
Enterprise value
$378.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.52
Price to sales (P/S)
1.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.3
Revenue
$114.7M
Gross profit
$114.7M
Operating income
-$59.92M
Net income
-$56.53M
EBIT
-$44.12M
EBITDA
-$39.97M
Free cash flow
-$3.47M
Per share
Balance sheet
Liquidity
EPS
-$0.25
EPS diluted
-$0.25
Free cash flow per share
-$0.02
Book value per share
$0.13
Revenue per share
$0.51
TBVPS
$1.39
Total assets
$315.29M
Total liabilities
$285.8M
Debt
$201.92M
Equity
$29.49M
Working capital
$264.88M
Debt to equity
6.85
Current ratio
6.88
Quick ratio
6.66
Net debt/EBITDA
-3.9
Margins
Efficiency
Dividend
EBITDA margin
-34.8%
Gross margin
100%
Net margin
-49.3%
Operating margin
-52.2%
Return on assets
-17.4%
Return on equity
-117.8%
Return on invested capital
-10.2%
Return on capital employed
-16.3%
Return on sales
-38.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GOSS stock price
How has the Gossamer Bio stock price performed over time
Intraday
-1.59%
1 week
-17.08%
1 month
-20.45%
1 year
-14.91%
YTD
8.17%
QTD
-11.05%
Financial performance
How have Gossamer Bio's revenue and profit performed over time
Revenue
$114.7M
Gross profit
$114.7M
Operating income
-$59.92M
Net income
-$56.53M
Gross margin
100%
Net margin
-49.3%
Gossamer Bio's net income has soared by 69% YoY and by 21% from the previous quarter
Gossamer Bio's operating income has surged by 67% YoY and by 18% QoQ
The net margin rose by 28% since the previous quarter
The operating margin is up by 24% since the previous quarter
Growth
What is Gossamer Bio's growth rate over time
Valuation
What is Gossamer Bio stock price valuation
P/E
N/A
P/B
7.52
P/S
1.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.3
GOSS's EPS has soared by 79% year-on-year and by 3.8% since the previous quarter
GOSS's equity has shrunk by 53% YoY and by 46% QoQ
The P/B is 29% more than the last 4 quarters average of 5.9 and 9% more than the 5-year quarterly average of 7.0
GOSS's revenue is up by 9% QoQ
Efficiency
How efficient is Gossamer Bio business performance
The company's return on equity has surged by 88% YoY and by 7% QoQ
Gossamer Bio's ROIC has soared by 77% YoY and by 21% from the previous quarter
GOSS's ROA has soared by 74% year-on-year and by 21% since the previous quarter
GOSS's ROS is up by 28% since the previous quarter
Dividends
What is GOSS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GOSS.
Financial health
How did Gossamer Bio financials performed over time
GOSS's total assets is 10% higher than its total liabilities
The current ratio has grown by 16% YoY and by 2.1% from the previous quarter
The quick ratio is up by 16% year-on-year
The company's debt to equity has surged by 106% YoY and by 84% QoQ
GOSS's equity has shrunk by 53% YoY and by 46% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.